Cerevance Media Center

Current News

June 26, 2023

Cerevance to Present at the Gordon Research Conference: Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases

Cerevance today announced plans to present a poster presentation at the upcoming Gordon Research Conference: Amyotrophic Lateral Sclerosis (ALS) andRelated Motor Neuron Diseases, taking place in Les Diablerets, VD, Switzerland,July 2 – July 7, 2023.

READ FULL

May 16, 2023

Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)

Cerevance today announced plans to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.

READ FULL

May 9, 2023

Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia,Canada, May 15 – 19, 2023.

READ FULL

May 8, 2023

Cerevance to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 2023 RBC Capital Markets Global Healthcare Conference being held May 16-17, 2023. Company management will also be available for virtual one-on-one meetings.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

August 31, 2023

22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium

Date:
Thursday, August 31, 2023
Time:
8:30am
Location:
Cambridge, United Kingdom
Media:
Presentation
Read full

July 10, 2023

Alzheimers Association International Conference

Date:
Sunday, July 16, 2023
Time:
8:45am – 4:15pm
Location:
Amsterdam, Netherlands
Media:
Presentation
Read full

June 28, 2023

XVI European Meeting on Glial Cells in Health and Disease

Date:
Monday, July 10, 2023
Time:
1:00pm – 4:00pm
Location:
Berlin, Germany
Media:
Poster
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

May 30, 2023

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, & W9 Pharmacokinetic Study of Escalating Single & Multiple Doses of CVN766, an OX1R Highly Selective Antagonist, in Healthy Subjects

Vitolo et al (2023) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766, an OX1R Highly Selective Antagonist in Healthy Subjects. American Society of Clinical Psychopharmacology, Miami Beach, Florida, USA.

view

May 9, 2023

Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease Using Cerevance’s NETSseq Platform and Analysis

Giuliano Stirparo, Xiao Xu, Marina Lizio, Justin Powell, Toni Cheung, Gonca Bayraktar, Louisa Christie, Megan Roberts, Gabriella Crane, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernadino Ossola, Nicola Brice, Keith Page, Lee A. Dawson & Mark Carlton (2023) Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease using Cerevance’s NETSseq Platform and Analysis. Keystone Meeting: Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development, Whi

view

May 2, 2023

Phase 1 Study of CVN424, a Novel GPR6 Inverse Agonist

Margolin, D.H., Brice, N.L., Davidson, A.M., Matthews, K.L., Carlton, M.B.L. (2022) Phase I, First- In-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel GPR6 Inverse Agonist for Parkinson’s Disease. J. Pharmacol. Exp. Ther. 381: 33– 41

view

April 1, 2023

CVN424, a Novel GPR6 Inverse Agonist Demonstrates Efficacy in an Adjunctive Parkinson’s Disease Phase 2 Clinical Trial

Karl Kieburtz, David Margolin, Jordon Dubow, Kim Matthews, Roland Burli, Lee A. Dawson, Naidong Ye, Mark B Carlton, Nicola L Brice (2023) CVN424, a novel GPR6 inverse agonist demonstrates efficacy in an adjunctive Parkinson’s Disease phase 2 clinical trial. Int Conf Alzheimer’s & Parkinson’s Diseases & related neurological disorders, Gothenburg, Sweden

view

March 31, 2023

NETSseq Reveals Deep Molecular Insights Into Alzheimer’s and Parkinson’s Disease and Facilitates Identification of Novel Therapeutic Targets

Xiao Xu, Giuliano Stirparo, Marina Lizio, Justin Powell, Toni Cheung, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernadino Ossola, Nicola Brice, Keith Page, Lee A. Dawson, Mark Carlton (2023) NETSseq reveals deep molecular insights into Alzheimer’s disease progression and facilitates identification of novel therapeutic targets. Int Conf Alzheimer’s & Parkinson’s Diseases & related neurological disorders, Gothenburg, Sweden

view

March 1, 2023

NETSseq Provides Deep Molecular Insights into Alzheimer’s Disease Progression Enabling Selection of Novel Therapeutic Targets

Louisa Christie, Xiao Xu, Giuliano Stirparo, Marina Lizio, Justin Powell, Louise Dickson, Toni Cheung, David Cadwalladr, Jason Lawrence, Steven Sheardown, Bernardino Ossola, Nicola Brice, Keith Page, Lee A. Dawson & Mark Carlton (2023) NETSseq Provides Deep Molecular Insights Into Alzheimer’s Disease Progression Enabling Selection Of Novel Therapeutic Targets For Drug Discovery. Alzheimer’s Research UK Conference, Aberdeen, UK.

view